Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review

Author(s): Shuo Li*, Linping Ke*, Xue Meng, Haiyan Zhou, Xiqin Zhang, Huaguo Wu, Jinming Yu*, Hui Zhang*

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 16 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Diagnosis of Leptomeningeal Metastases (LM) from Non-Small Cell Lung Cancer (NSCLC) is usually based on clinical symptoms, Cerebral-Spinal Fluid (CSF) cytology, and neuro-imaging. However, early diagnosis of LM in NSCLC is challenging due to the low sensitivity of these approaches. The Next-Generation Sequencing (NGS) using CSF could help improve the diagnosis of LM and guide its treatment options.

Case Presentation: We report a 39-year-old male NSCLC patient with negative molecular testing results in the lung cancer tissue sample. The patient developed symptoms of LM with the negative CSF cytology and MRI; however, the NGS analysis of CSF revealed an EGFR exon 19 del mutation. The patient attained 6 months of Progression-Free Survival (PFS) by treating with erlotinib and anlotinib before the neurological symptoms appeared again. EGFR Thr790Met was positive in the CSF but negative in his plasma. The patient was then treated with osimertinib therapy and the response was maintained for more than 1 year.

Results & Discussion: This case is the first study reporting the clinical benefit of using the combination of erlotinib and anlotinib for the treatment of LM with the EGFR 19 del, osimertinib with EGFR T790M mutation in CSF, but negative gene mutation in the blood or lung tumor biopsy specimens. Our results support that genetic analysis should be performed with CSF samples in all cases of suspected LM when the results of testing for EGFR/ALK/ROS1 mutation in blood samples or tumor biopsy specimens are negative, as these patients could benefit from treatment of TKIs in a poor prognostic setting.

Conclusion: In parallel to current patents, NGS could be applied as a novel strategy in the managing of NSCLC patients with LM.

Keywords: Cerebral-spinal fluid, leptomeningeal metastases, next generation sequencing, non-small cell lung cancer, osimertinib, tumor heterogeneity.

[1]
Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 2018; 19(1): e43-55.
[http://dx.doi.org/10.1016/S1470-2045(17)30689-7] [PMID: 29304362]
[2]
Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev 2017; 53: 128-37.
[http://dx.doi.org/10.1016/j.ctrv.2016.12.006] [PMID: 28110254]
[3]
Patil S, Rathnum KK. Management of leptomeningeal metastases in non-small cell lung cancer. Indian J Cancer 2019; 56(Suppl.): S1-9.
[http://dx.doi.org/10.4103/ijc.IJC_74_19] [PMID: 31793437]
[4]
Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 2016; 11(11): 1962-9.
[http://dx.doi.org/10.1016/j.jtho.2016.06.029] [PMID: 27539328]
[5]
Kuiper JL, Hendriks LE, van der Wekken AJ, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer 2015; 89(3): 255-61.
[http://dx.doi.org/10.1016/j.lungcan.2015.05.023] [PMID: 26117231]
[6]
Shah V, Kochar P. Implication to disease, therapeutic strategies and tumor targeted drug delivery approaches. Recent Pat Anticancer Drug Discov 2018; 13(1): 70-85.
[PMID: 29189177]
[7]
Chamberlain M, Soffietti R, Raizer J, et al. Leptomeningeal metastasis: A response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-oncol 2014; 16(9): 1176-85.
[PMID: 24867803]
[8]
Nabors LB, Portnow J, Ammirati M, et al. NCCN Guidelines Insights: Central nervous system cancers, version 1.2017. J Natl Compr Canc Netw 2017; 15(11): 1331-45.
[PMID: 29118226]
[9]
Liao BC, Lee JH, Lin CC, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 2015; 10(12): 1754-61.
[PMID: 26334749]
[10]
Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer 2018; 124(1): 21-35.
[http://dx.doi.org/10.1002/cncr.30911] [PMID: 29165794]
[11]
Ma C, Lv Y, Jiang R, Li J, Wang B, Sun L. Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer. Oncol Lett 2016; 11(1): 619-23.
[12]
Jamal-Hanjani M, Wilson GA, McGranahan N, et al. TRACERx consortium. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017; 376(22): 2109-21.
[http://dx.doi.org/10.1056/NEJMoa1616288] [PMID: 28445112]
[13]
De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839.
[http://dx.doi.org/10.1038/ncomms9839] [PMID: 26554728]
[14]
Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 2015; 5(11): 1164-77.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0369] [PMID: 26410082]
[15]
Zheng MM, Li YS, Jiang BY, et al. Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC. J Thorac Oncol 2019; 14(5): 924-32.
[http://dx.doi.org/10.1016/j.jtho.2019.01.007] [PMID: 30659989]
[16]
Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 2016; 34(20): 2404-15.
[http://dx.doi.org/10.1200/JCO.2016.66.6487] [PMID: 27161972]
[17]
Shingyoji M, Kageyama H, Sakaida T, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol 2011; 6(7): 1215-20.
[http://dx.doi.org/10.1097/JTO.0b013e318219aaae] [PMID: 21610522]
[18]
Ballester LY, Glitza Oliva IC, Douse DY, et al. Evaluating circulating tumor DNA from the cerebrospinal fluid of patients with melanoma and leptomeningeal disease. J Neuropathol Exp Neurol 2018; 77(7): 628-35.
[http://dx.doi.org/10.1093/jnen/nly046] [PMID: 29873738]
[19]
Zhao Y, He JY, Zou YL, et al. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis. BMC Neurol 2019; 19(1): 331.
[http://dx.doi.org/10.1186/s12883-019-1554-5] [PMID: 31856745]
[20]
Li YS, Jiang BY, Yang JJ, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol 2018; 29(4): 945-52.
[http://dx.doi.org/10.1093/annonc/mdy009] [PMID: 29346604]
[21]
Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA 2015; 112(31): 9704-9.
[http://dx.doi.org/10.1073/pnas.1511694112] [PMID: 26195750]
[22]
Sasaki S, Yoshioka Y, Ko R, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig 2016; 54(1): 14-9.
[http://dx.doi.org/10.1016/j.resinv.2015.07.001] [PMID: 26718140]
[23]
Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 2015; 61(3): 514-22.
[http://dx.doi.org/10.1373/clinchem.2014.235457] [PMID: 25605683]
[24]
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018; 15(2): 81-94.
[http://dx.doi.org/10.1038/nrclinonc.2017.166] [PMID: 29115304]
[25]
Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467(7319): 1109-13.
[http://dx.doi.org/10.1038/nature09460] [PMID: 20981101]
[26]
Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 2014; 15(8): 453.
[http://dx.doi.org/10.1186/s13059-014-0453-8] [PMID: 25222836]
[27]
Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467(7319): 1114-7.
[http://dx.doi.org/10.1038/nature09515] [PMID: 20981102]
[28]
Giardina T, Robinson C, Grieu-Iacopetta F, et al. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. Pathology 2018; 50(4): 389-401.
[http://dx.doi.org/10.1016/j.pathol.2018.01.005] [PMID: 29752127]
[29]
Kim YH, Song Y, Kim JK, et al. False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases. PLoS One 2019; 14(9): e0222535.
[http://dx.doi.org/10.1371/journal.pone.0222535] [PMID: 31513681]
[30]
Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 2015; 10(11): 1553-9.
[http://dx.doi.org/10.1097/JTO.0000000000000647] [PMID: 26309190]
[31]
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3(75): 75ra26.
[http://dx.doi.org/10.1126/scitranslmed.3002003] [PMID: 21430269]
[32]
Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19(8): 2240-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-2246] [PMID: 23470965]
[33]
Bivona TG, Doebele RC. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med 2016; 22(5): 472-8.
[http://dx.doi.org/10.1038/nm.4091] [PMID: 27149220]
[34]
Ramirez M, Rajaram S, Steininger RJ, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 2016; 7: 10690.
[http://dx.doi.org/10.1038/ncomms10690] [PMID: 26891683]
[35]
Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005; 7(3): 396-403.
[http://dx.doi.org/10.1016/S1525-1578(10)60569-7] [PMID: 16049312]
[36]
Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362(25): 2380-8.
[http://dx.doi.org/10.1056/NEJMoa0909530] [PMID: 20573926]
[37]
Mitsudomi T, Morita S, Yatabe Y, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11(2): 121-8.
[http://dx.doi.org/10.1016/S1470-2045(09)70364-X] [PMID: 20022809]
[38]
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-57.
[http://dx.doi.org/10.1056/NEJMoa0810699] [PMID: 19692680]
[39]
Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13(3): 239-46.
[http://dx.doi.org/10.1016/S1470-2045(11)70393-X] [PMID: 22285168]
[40]
Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26(9): 1883-9.
[http://dx.doi.org/10.1093/annonc/mdv270] [PMID: 26105600]
[41]
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12(8): 735-42.
[http://dx.doi.org/10.1016/S1470-2045(11)70184-X] [PMID: 21783417]
[42]
Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: Which tyrosine kinase inhibitor and when? Future Oncol 2018; 14(11): 1117-32.
[http://dx.doi.org/10.2217/fon-2017-0636] [PMID: 29336166]
[43]
Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 2018; 109(4): 1207-19.
[http://dx.doi.org/10.1111/cas.13536] [PMID: 29446853]
[44]
Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 2018; 4(11): 1569-75.
[http://dx.doi.org/10.1001/jamaoncol.2018.3039] [PMID: 30098152]
[45]
Wang L, He Z, Yang S, et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): A subgroup analysis of ALTER0303 trial. Transl Lung Cancer Res 2019; 8(5): 575-83.
[http://dx.doi.org/10.21037/tlcr.2019.09.21] [PMID: 31737494]
[46]
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15(11): 1236-44.
[http://dx.doi.org/10.1016/S1470-2045(14)70381-X] [PMID: 25175099]
[47]
Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 2019; 20(5): 625-35.
[PMID: 30975627]
[48]
Chikaishi Y, Kanayama M, Taira A, et al. Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer. Ann Transl Med 2018; 6(20): 401.
[PMID: 30498728]
[49]
Sakata Y, Kawamura K, Shingu N, Ichikado K. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer. Lung Cancer 2016; 99: 120-2.
[PMID: 27565925]
[50]
Bearz A, Cecco S, Francescon S, Re FL, Corona G, Baldo P. Safety profiles and pharmacovigilance considerations for recently patented anticancer Drugs: Lung cancer. Recent Pat Anticancer Drug Discov 2019; 14(3): 242-57.
[http://dx.doi.org/10.2174/1574892814666190726124735] [PMID: 31362665]
[51]
Santarpia M, Liguori A, Karachaliou N, et al. Osimertinib in the treatment of non-small-cell lung cancer: Design, development and place in therapy. Lung Cancer (Auckl) 2017; 8: 109-25.
[http://dx.doi.org/10.2147/LCTT.S119644] [PMID: 28860885]
[52]
Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22(20): 5130-40.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0399] [PMID: 27435396]
[53]
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378(2): 113-25.
[http://dx.doi.org/10.1056/NEJMoa1713137] [PMID: 29151359]
[54]
Yohe S, Thyagarajan B. Review of clinical next-generation sequencing. Arch Pathol Lab Med 2017; 141(11): 1544-57.
[http://dx.doi.org/10.5858/arpa.2016-0501-RA] [PMID: 28782984]
[55]
Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019; 45(7): 661-73.
[http://dx.doi.org/10.1055/s-0039-1688446] [PMID: 31096307]
[56]
Slatko BE, Gardner AF, Ausubel FM. Overview of next-generation sequencing technologies. Curr Protoc Mol Biol 2018; 122(1): e59.
[http://dx.doi.org/10.1002/cpmb.59] [PMID: 29851291]
[57]
Kamps R, Brandão RD, Bosch BJ, et al. Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci 2017; 18(2): E308.
[http://dx.doi.org/10.3390/ijms18020308] [PMID: 28146134]
[58]
Grumolato L. Methods for preventing of treating cancer resistance to EGFR inhibition. EP3641818, 2020.
[59]
Jin J. Application of cryptotanshinone in preparation of drug for overcoming drug resistance of NSCLC therapeutic drug EGFR-TKI. CN111000850, 2020.
[60]
Antonio M. Combination for treating cancer. WO2020016377, 2020.
[61]
Zhou C. Method and application of autophagy inhibitor for overcoming drug resistance in treatment of lung cancer. CN110496125, 2019.
[62]
Yonesaka K. Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate. WO2018159582, 2018.
[63]
Katayama R. Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance. WO2017200016, 2017.
[64]
Wu Y. Miazines compound, EGFR inhibitor and application thereof. CN107382879, 2017.
[65]
Shen B. EGFR-TK (Epidermal Growth Factor Receptor Tyrosine Kinase) inhibitor BF3-AZD9291 with antitumor activity as well as preparation method and application of EGFR-TK inhibitor BF3-AZD9291. CN107501240, 2017.


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2021
Published on: 26 November, 2020
Page: [108 - 116]
Pages: 9
DOI: 10.2174/1574892815666201127114224

Article Metrics

PDF: 112
HTML: 3